Related Experiment Videos
Management of advanced prostate cancer
G Auclerc1, E C Antoine, F Cajfinger
1SOMPS, Salpêtrière Hospital, Department of Medical Oncology, Paris, France.
The Oncologist
|March 8, 2000
Summary
Combined androgen blockade improves survival in advanced prostate cancer when combined with specific hormonal therapies. Further treatments and pain management options exist for advanced or hormone-refractory disease.
Area of Science:
- Oncology
- Urology
Background:
- Advanced prostate cancer is often hormone-sensitive.
- Hormonal therapies are a cornerstone of treatment.
Purpose of the Study:
- To review current and novel treatment strategies for advanced prostate cancer.
- To discuss management of hormone-refractory disease and bone metastases.
Main Methods:
- Review of current literature on hormonal blockade and subsequent therapies.
- Discussion of palliative care options for bone lesions.
Main Results:
- Combined androgen blockade (CAB) with luteinizing-hormone-releasing hormone analogs and non-steroidal antiandrogens improves survival and quality of life.
- Antiandrogen withdrawal, estrogens, aromatase inhibitors, and cytotoxic agents are effective in later stages.
- Radiotherapy, biphosphonates, and radioisotopes offer pain relief for bone metastases.
Conclusions:
- Optimal hormonal blockade strategies enhance outcomes in advanced prostate cancer.
- A range of treatments are available for disease progression and symptom management.
- New evaluation methods will facilitate clinical trial advancements.